214 related articles for article (PubMed ID: 18820850)
1. [Bisphosphonate-associated osteonecrosis of the jaw].
Krauth MT; Fügl A; Gruber R
Wien Klin Wochenschr; 2008; 120(15-16):467-76. PubMed ID: 18820850
[TBL] [Abstract][Full Text] [Related]
2. [Bisphosphonates and osteonecrosis of the jaws].
Urade M
Clin Calcium; 2007 Feb; 17(2):241-8. PubMed ID: 17272882
[TBL] [Abstract][Full Text] [Related]
3. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ
J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
[TBL] [Abstract][Full Text] [Related]
4. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate-related osteonecrosis of the jaw: model and diagnosis with cone beam computerized tomography.
Barragan-Adjemian C; Lausten L; Ang DB; Johnson M; Katz J; Bonewald LF
Cells Tissues Organs; 2009; 189(1-4):284-8. PubMed ID: 18703870
[TBL] [Abstract][Full Text] [Related]
7. Osteonecrosis of the jaw in patients on bisphosphonate treatment. review of literature with contribution of a case of multiple myeloma.
Goranova-Marinova VS; Pechalova-Petrova PF; Goranov SG
Folia Med (Plovdiv); 2009; 51(4):53-7. PubMed ID: 20232660
[TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.
Yarom N; Yahalom R; Shoshani Y; Hamed W; Regev E; Elad S
Osteoporos Int; 2007 Oct; 18(10):1363-70. PubMed ID: 17598065
[TBL] [Abstract][Full Text] [Related]
9. Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Gabbert TI; Hoffmeister B; Felsenberg D
J Cancer Res Clin Oncol; 2015 Apr; 141(4):749-58. PubMed ID: 25319961
[TBL] [Abstract][Full Text] [Related]
10. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
11. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
King AE; Umland EM
Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonate associated osteonecrosis of the jaw.
Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Lentle B; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Mardini MA; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; Ste-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
J Rheumatol; 2009 Mar; 36(3):478-90. PubMed ID: 19286860
[TBL] [Abstract][Full Text] [Related]
13. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
O'Ryan FS; Khoury S; Liao W; Han MM; Hui RL; Baer D; Martin D; Liberty D; Lo JC
J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Vahtsevanos K; Kyrgidis A; Verrou E; Katodritou E; Triaridis S; Andreadis CG; Boukovinas I; Koloutsos GE; Teleioudis Z; Kitikidou K; Paraskevopoulos P; Zervas K; Antoniades K
J Clin Oncol; 2009 Nov; 27(32):5356-62. PubMed ID: 19805682
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF
Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574
[TBL] [Abstract][Full Text] [Related]
16. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G
Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788
[TBL] [Abstract][Full Text] [Related]
18. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
Abu-Id MH; Warnke PH; Gottschalk J; Springer I; Wiltfang J; Acil Y; Russo PA; Kreusch T
J Craniomaxillofac Surg; 2008 Mar; 36(2):95-103. PubMed ID: 18234504
[TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
Van Poznak C; Estilo C
Oncology (Williston Park); 2006 Aug; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349
[TBL] [Abstract][Full Text] [Related]
20. Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis.
Tubiana-Hulin M; Spielmann M; Roux C; Campone M; Zelek L; Gligorov J; Samson J; Lesclous P; Laredo JD; Namer M
Crit Rev Oncol Hematol; 2009 Jul; 71(1):12-21. PubMed ID: 19070505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
